Ondine Biomedical Share Discussion Threads

[jailbird] 01/12/2024 21:07

Explains M&G investment strategy and can see why they bought in here

Can Pension Funds Fuel The Growth Of UK Life Sciences?

hxxps://www.linkedin.com/pulse/can-pension-funds-fuel-growth-uk-life-sciences-matthew-neal-syade

Last week, ahead of the Mansion House speech, 5654 & Company hosted a networking breakfast with Citi Peel Hunt , LSEG (London Stock Exchange Group) and Covington & Burling LLP . The event brought together life sciences companies and investors for a keynote address, panel discussions, and a fireside chat on the potential impact of pension funds channelling their capital into growth opportunities, specifically to support the UK’s life sciences industry.
Investors such as Legal & General , Phoenix Group , Schroders Capital , M&G plc and Aviva Investors are well-positioned to lead this shift. He also discussed the untapped potential of the £400 billion in Local Government Pension Schemes (LGPS). The next day we heard the Chancellor’s intentions to consolidate LGPS into eight ‘MegaFundsR17;.


On the second panel, discussion centred around building critical mass in the UK life sciences market that will create competition and attract public market investors back to the sector. While Nasdaq dominates biotech listings, and will likely do so for some time, the UK’s strengths in medical devices, healthtech, tools, services and manufacturing should not be undersold and there is a route to the public markets for these. M&G's track record of success supporting the growth of UK life sciences companies through patient investment was also highlighted. This includes world leaders in their fields including Oxford Nanopore Technologies and Oxford Biomedica , and more recently it has invested into 4basebio and Ondine Biomedical Inc.

To attract investment, life sciences companies must present clear narratives and compelling equity stories. Transparent pension products focusing on tech and life sciences could shift investor perspectives from early-stage losses to long-term growth. By fostering collaboration between venture capital, pension funds, and institutions like the BBB, the UK can solidify its position as a global leader in life sciences innovation and compete effectively in the global market.

[jailbird] 29/11/2024 10:05

Fortunate to be Adding under placing price

[jailbird] 26/11/2024 08:53

Wonder if there is another Tr1 toCome , not sure if all the recent funding shares are in these numbers now

[jailbird] 26/11/2024 08:50

Nice summary

[jailbird] 25/11/2024 20:44

RNS - There is the M&G holding of 10.3% / 40m+ shares

[jailbird] 23/11/2024 21:25

From 3 mins onwards Fascinating and informative interview Must listen , be patient as gets betterEnds at 50 mins 38 mins - spent £250m developing this major breakthrough protocol treatment , become standard of care globally Compare that with £2.5 billion to develop an antibioticGet phase 3 granted , talking millions of patients who will using this Talks about Vancouver and NHS hospital take ups too https://youtu.be/hIKXAqkDKo8?si=qjkhibAwKPUl4tnNShedding light on the invisible enemy, Dr. Nicholas Lobel reveals the illuminating potential of photodisinfection to transform healthcare. Dr. Loebel serves as President and Chief Technology Officer (CTO) of Ondine Biomedical. Beyond the growing ineffectiveness of antibiotics, Dr. Loebel delves into the brilliance of using light to zap harmful microbes. Get ready to nerd out with the guys as they learn about how photodisinfection targets bacteria with laser-like precision on various surfaces and even within body cavities (right up the ol' schnoz), distinguishing itself from other light-based treatments. Dr. Lobel highlights the critical role of nasal decolonization in preventing hospital-acquired infections, showcasing impressive success stories and the untapped potential of this approach.

[jailbird] 22/11/2024 17:47

Btw this is not a fleeting investment for me now . I am invested in this for the longer term I have called it right upto now when others were buying higher

[jailbird] 22/11/2024 17:44

BambooMy final say on this , I do not want me to post here , just say I share and engage with the proper investors and can agree or disagree with respectful investors , but have no time for penny herd traders who spread misinformation and attack you when you have a contrary view or challenge them

[jailbird] 22/11/2024 16:11

I see Zico has sold up at a loss and bought GDR .He will need that to rise fourfold to make his money back after selling hereCompany has a good product used only for TIA and babies at risk of hearing loss The market they are competing into is only $320m globally Which is small compared to the $billions OBI are targeting Plus with more shares in issue and you can see more money needed for clinical testing , revenues achievable will be lot less in comparison too His loss

[jailbird] 22/11/2024 12:36

BoD own 40% of company

[jailbird] 22/11/2024 12:18

Another Tr1Albemarle Life Sciences Fund have bought 3.83% as part of placing

[z1co] 22/11/2024 11:15

Sold out completely and reinvested in GDR , which is only capped @ £13m compared to OBI valuation of £33m.

US phase trials should have been completed by now.

[bamboo2] 22/11/2024 09:02

TR-1 for directors


Director Total number of common shares % of issued share capital

Carolyn Cross 155,864,029 38.58%

Nicolas Loebel 3,513,991 0.87%

Junaid Bajwa 1,193,697 0.30%

Jean Duval 1,163,529 0.29%

Michael Farrar 484,806 0.12%

Jean Charest 353,356 0.09%

Margaret Shaw 213,853 0.05%

[jailbird] 18/11/2024 18:00

tbd11,

yes just seen this first RNS of major holdings after fund raise

[thebd11] 18/11/2024 17:15

And so the TR-1s begin. I'd expect another soon - high single or low double digits holding most likely. Some big institutions backing this, good to see!

[thebd11] 18/11/2024 13:02

I would expect so. One large institution has taken a very reasonably sized position - more to follow soon

[jailbird] 18/11/2024 07:39

I know M&G have bought in

[bamboo2] 18/11/2024 07:32

I hope the new shares issued this week should flush out some TR-1 holding notices.

[jailbird] 15/11/2024 16:09

Funding sorted until end of 2025, with another tranche due with Canadian investment will take cash resources to early 2027

[jailbird] 15/11/2024 10:54

100k buyer back today Noticed this buying trend recently